

Panion's shareholders benefit from CombiGene's successful funding

The financing of the production development process of CombiGene's - and therefore also Panion's - gene therapy product is now secured, according to the press release from CombiGene on 22nd of August 2018.

With the unusually large EU-contribution of 3.36 million Euro granted to CombiGene in the Horizon 2020 programme earlier this year and supplemented with the new directed shares emission, which is signed for 75% in advance, the product development is funded and can continue according to plan.

It is very positive for Panion's shareholders that CombiGene has secured the financing of the development process for the gene therapy product CG01 for treatment of drug refractory epilepsy in humans, because Panion's gene therapy product for dogs builds on the same technology. Therefore, CombiGene's success paves the way for Panion's success.

With the license agreement between CombiGene and Panion, the product manufacturing process is the most essential step in getting a product to the market.



"It is very uplifting and good news from CombiGene, and we in Panion follow the development closely. Personally, I congratulate CombiGene's management for the very skilful, well-managed, and persistent work on getting the adequate funding in place. Another big step towards the goal", says CEO of Panion, Anja Holm.



Ánja E. H. Holm, CEO | + 45-22 94 66 00 anja.holm@panion-animalhealth.com

Developing animal health – Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases. Panion Animal Health AB is listed at Spotlight Stock Market.

Panion Animal Health AB

info@panion-animalhealth.com

linkedin.com/company/panion-animalhealth







